Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies

@inproceedings{Gore2011ChallengesAO,
  title={Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies},
  author={Martin Eric Gore and James M. G. Larkin},
  booktitle={British Journal of Cancer},
  year={2011}
}
Optimum efficacy is the primary goal for any cancer therapy, and entails controlling tumour growth and prolonging survival as far as possible. The prognosis for patients with metastatic renal cell carcinoma (mRCC) has greatly improved with the introduction of targeted therapies. This review examines the development and efficacy of targeted agents for the management of mRCC, the challenges offered by their rapid emergence, and discusses how mRCC treatment may evolve in the future. Improvements… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 31 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 52 references

Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone

  • JP Dutcher, D Wild, +5 authors BI Rini
  • Poster presented at the 44th Annual Meeting of…
  • 2008
Highly Influential
1 Excerpt

Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma. American Society for Clinical Oncology – Genitourinary Cancers Symposium

  • BI Rini, TE Hutson, +5 authors BJ Escudier
  • 2010
2 Excerpts

Similar Papers

Loading similar papers…